Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 18 of 18 results for apremilast

  1. Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

    Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    8 August 2018
    View recommendations

    Sections for TA537

  2. Apremilast for treating active psoriatic arthritis (TA372)

    This guidance has been updated and replaced by NICE technology appraisal guidance 433.

    Technology appraisal guidance
    Published
    16 December 2015

  3. Apremilast for treating moderate to severe plaque psoriasis (TA368)

    Technology appraisal guidance
    Published
    25 November 2015